Predictors of recurrence of atrial fibrillation within the first 3 months after ablation
Standard
Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. / Zink, Matthias Daniel; Chua, Winnie; Zeemering, Stef; di Biase, Luigi; Antoni, Bayes de Luna; David, Callans; Hindricks, Gerhard; Haeusler, Karl Georg; Al-Khalidi, Hussein R; Piccini, Jonathan P; Mont, Lluís; Nielsen, Jens Cosedis; Escobar, Luis Alberto; de Bono, Joseph; Van Gelder, Isabelle C; de Potter, Tom; Scherr, Daniel; Themistoclakis, Sakis; Todd, Derick; Kirchhof, Paulus; Schotten, Ulrich.
In: EUROPACE, Vol. 22, No. 9, 01.09.2020, p. 1337-1344.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predictors of recurrence of atrial fibrillation within the first 3 months after ablation
AU - Zink, Matthias Daniel
AU - Chua, Winnie
AU - Zeemering, Stef
AU - di Biase, Luigi
AU - Antoni, Bayes de Luna
AU - David, Callans
AU - Hindricks, Gerhard
AU - Haeusler, Karl Georg
AU - Al-Khalidi, Hussein R
AU - Piccini, Jonathan P
AU - Mont, Lluís
AU - Nielsen, Jens Cosedis
AU - Escobar, Luis Alberto
AU - de Bono, Joseph
AU - Van Gelder, Isabelle C
AU - de Potter, Tom
AU - Scherr, Daniel
AU - Themistoclakis, Sakis
AU - Todd, Derick
AU - Kirchhof, Paulus
AU - Schotten, Ulrich
N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.METHODS AND RESULTS: We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).CONCLUSION: Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02227550.
AB - AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.METHODS AND RESULTS: We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).CONCLUSION: Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02227550.
KW - Aged
KW - Atrial Fibrillation/diagnosis
KW - Catheter Ablation/adverse effects
KW - Female
KW - Humans
KW - Recurrence
KW - Retrospective Studies
KW - Risk Factors
KW - Treatment Outcome
U2 - 10.1093/europace/euaa132
DO - 10.1093/europace/euaa132
M3 - SCORING: Journal article
C2 - 32725107
VL - 22
SP - 1337
EP - 1344
JO - EUROPACE
JF - EUROPACE
SN - 1099-5129
IS - 9
ER -